Earnings summaries and quarterly performance for MiNK Therapeutics.
Executive leadership at MiNK Therapeutics.
Board of directors at MiNK Therapeutics.
Research analysts who have asked questions during MiNK Therapeutics earnings calls.
Emily Bodnar
H.C. Wainwright & Co.
6 questions for INKT
Also covers: AGEN, AGIO, ATOS +6 more
Mayank Mamtani
B. Riley Securities
4 questions for INKT
Also covers: AGEN, ALT, ARWR +18 more
Matthew Phipps
William Blair
2 questions for INKT
Also covers: ABBV, AGEN, AMGN +8 more
Charles Moore
Robert W. Baird & Co.
1 question for INKT
Also covers: CRNX
Jack Allen
Robert W. Baird & Co.
1 question for INKT
Also covers: ALLO, BLUE, CLLS +6 more
Recent press releases and 8-K filings for INKT.
MiNK Therapeutics Initiates Phase 1 Trial for AgenT-797 in GvHD Prevention
INKT
Product Launch
New Projects/Investments
- MiNK Therapeutics (INKT) announced the initiation of a Phase 1 clinical trial for its lead therapy, agenT-797, to assess its safety and efficacy in reducing graft-versus-host disease (GvHD) and other complications in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT).
- The trial is supported by non-dilutive public-private funding, including an NIH STTR grant from NIAID and the Mary Gooze Clinical Trial Award.
- This marks an expansion of MiNK's iNKT platform into transplantation with an off-the-shelf, HLA-independent, lymphodepletion-free experimental therapy.
Jan 8, 2026, 5:00 PM
MiNK Therapeutics Reports Q3 2025 Results and Advances iNKT Platform
INKT
Earnings
New Projects/Investments
Management Change
- MiNK Therapeutics reported a net loss of $2.9 million, or $0.65 per share, for Q3 2025, compared to a net loss of $1.8 million, or $0.46 per share, for Q3 2024.
- The company ended Q3 2025 with approximately $14.3 million in cash and cash equivalents, and subsequently raised $1.2 million through equity sales, extending its cash runway through 2026.
- New clinical data for agenT-797 showed durable remissions and long-tail survivors, including complete remissions lasting over two years in chemotherapy- and checkpoint-refractory cancers, with a favorable safety profile.
- MiNK is accelerating its iNKT platform, launching a GvHD trial with non-dilutive funding and a Phase 2+ trial in severe pulmonary disease with FDA-validated endpoints, targeting first patient dosing for the pulmonary trial by early Q1 2026.
- The company's manufacturing process yields 1 billion cells per donor, allowing for stockpiling and stability for almost three years, with ongoing discussions for non-dilutive financing to support expansion.
Dec 8, 2025, 9:10 PM
MiNK Therapeutics Reports Q3 2025 Financials and Provides Clinical Program Updates
INKT
Earnings
Product Launch
Board Change
- MiNK Therapeutics reported a net loss of $2.9 million, or $0.65 per share, for the third quarter of 2025, and ended the quarter with a cash balance of $14.3 million, providing a cash runway through 2026.
- The company presented updated clinical data for agenT-797 in relapsed or refractory solid tumors, observing a median overall survival of approximately 23 months in patients receiving combination therapy with PD-1, and a complete remission in a patient with metastatic testicular cancer.
- MiNK Therapeutics is advancing new clinical programs, including a grant-funded phase I study for immune reconstitution following stem cell transplantation (GVHD) and a global phase II/III clinical trial for acute pulmonary dysfunction with multi-drug resistant infections, with the latter targeting first patient dosing by early Q1 2026.
- The company strengthened its leadership team by welcoming Dr. John Holcomb to its Board of Directors and Dr. Therese Hammond as Head of Development.
Nov 14, 2025, 1:30 PM
MiNK Therapeutics Reports Q3 2025 Financials and Clinical Progress
INKT
Earnings
Guidance Update
New Projects/Investments
- MiNK Therapeutics reported a net loss of $2.9 million (or $0.65 per share) for Q3 2025, compared to $1.8 million (or $0.46 per share) for Q3 2024. For the nine months ended September 30, 2025, the net loss was $9.9 million (or $2.39 per share), compared to $8.3 million (or $2.24 per share) for the same period in 2024.
- The company ended Q3 2025 with a cash balance of $14.3 million and has since raised an additional $1.2 million through an at-the-market sales agreement, providing a cash runway through 2026.
- Updated clinical data for agenT-797 in relapsed or refractory solid tumors showed a median overall survival of approximately 23 months when administered in combination with PD-1, with no observed cytokine release syndrome, neurotoxicity, or graft versus host disease.
- MiNK Therapeutics is preparing to launch a global Phase II/III clinical trial for acute pulmonary dysfunction and a grant-funded Phase I study for graft versus host disease (GvHD), with the pulmonary trial targeting first patient dosing by very early Q1 2026. The company is now a fully independent operating company and has strengthened its leadership team.
Nov 14, 2025, 1:30 PM
MiNK Therapeutics Reports Q3 2025 Financials and Clinical Progress
INKT
Earnings
Product Launch
New Projects/Investments
- MiNK Therapeutics reported a net loss of $2.9 million (or $0.65 per share) for Q3 2025 and ended the quarter with a cash balance of $14.3 million, supplemented by an additional $1.2 million raised post-quarter, providing a cash runway through 2026.
- The company presented updated clinical data for agenT-797 in relapsed or refractory solid tumors, demonstrating a median overall survival of approximately 23 months in combination with PD-1, including observations of complete remission and durable partial responses.
- MiNK is advancing its clinical pipeline with the imminent launch of a global Phase II (potentially Phase II-III) trial for acute pulmonary dysfunction and a grant-funded Phase I study for graft versus host disease (GVHD).
- Manufacturing capabilities have been significantly enhanced, now yielding billions of cells per donor, which supports stockpiling and offers cost advantages, with ongoing efforts to secure non-dilutive financing.
Nov 14, 2025, 1:30 PM
MiNK Therapeutics Reports Q3 2025 Results and Clinical Progress
INKT
Earnings
New Projects/Investments
Management Change
- MiNK Therapeutics reported a net loss of $2.9 million for Q3 2025, or $0.65 per share, and ended the quarter with approximately $14.3 million in cash and cash equivalents, extending its cash runway through 2026.
- The company highlighted durable clinical responses with its lead asset agenT-797 in refractory solid tumors, including complete remissions lasting over two years.
- MiNK is expanding its iNKT platform, launching a GVHD trial through non-dilutive funding and a Phase 2+ trial in severe pulmonary disease with FDA-validated endpoints.
- Dr. Terese C. Hammond joined as Head of Inflammatory and Pulmonary Diseases, and Colonel (Ret.) John B. Holcomb, MD, FACS joined the Board of Directors, strengthening the leadership team.
Nov 14, 2025, 12:30 PM
MiNK Therapeutics to Report Q3 2025 Financial Results
INKT
Earnings
New Projects/Investments
- MiNK Therapeutics (INKT) will release its third quarter 2025 financial results before market open on Friday, November 14th.
- A conference call and webcast will be held at 8:30 a.m. ET on November 14th to discuss financial results, recent clinical progress, and upcoming corporate milestones.
- This announcement follows the company's late-breaking presentation at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting, where new clinical data for its agenT-797 iNKT cell therapy demonstrated durable immune reconstitution and signals of activity in patients with advanced solid tumors.
Nov 5, 2025, 2:07 PM
Quarterly earnings call transcripts for MiNK Therapeutics.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more